Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma

Experimental and Clinical Endocrinology and Diabetes

Volumn 110, Issue 7, 2002, Pages 364-369

  Seiler, Lysann ^a   Braune, S ^a   Borm, K ^a   Magerkurth, C ^a   Talazko, J ^a   Peters, T ^a   Reincke, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Autonomic failure; Orthostatic hypotension; Prolactinoma

Indexed keywords

ADRENALIN; CABERGOLINE; CORTICOTROPIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETILEFRINE; FLUDROCORTISONE; FOLLITROPIN; HYDROCORTISONE; LIOTHYRONINE; LUTEINIZING HORMONE; NORADRENALIN; PIROXICAM; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADRENALIN BLOOD LEVEL; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; CLINICAL EXAMINATION; DOPAMINE BLOOD LEVEL; HUMAN; LEG COMPRESSION; MALE; NORADRENALIN BLOOD LEVEL; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTINOMA; REHYDRATION; SYMPATHETIC TONE; VERTIGO;

ADRENERGIC AGONISTS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTONOMIC NERVOUS SYSTEM DISEASES; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; ETILEFRINE; FLUDROCORTISONE; HORMONES; HUMANS; IMPOTENCE; MAGNETIC RESONANCE IMAGING; MALE; PIROXICAM; PITUITARY NEOPLASMS; PROLACTINOMA; VALSALVA MANEUVER; VERTIGO;

EID: 0036802302     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34995     Document Type: Article

References (32)

1. American Autonomic Society and American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Autonomic Res 1996; 6: 125-126
2. Arai K, Kato N, Kashiwado K, Hattori T. Pure autonomic failure in association with human alpha-synucleinopathy. Neuroscience Letters 296 (2-3): 171-173, 2000
3. Becker K, Keuser R, Weber M, Steffen HM. Autonomic failure as the cause of vertigo and prolactinoma. Med Klin 90 (7): 398-402, 1995
4. Bernard A, Koch J, Vetter W. Prevalence of hypotension and symptomatic, orthostatic dysregulation in a patient sample of a medical polyclinic. Schweiz Rundsch Med Prax 88 (13): 547-558, 1999
5. Colao A, Annunziato L, Lombardi G. Treatment of prolactinoma. Ann Med 30 (5): 452-459, 1998
6. Dae MW, O'Connell JW, Botvinick EH. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 79 (3): 534-644, 1989
7. Esler M, Jackman G, Kelleher D, Skewa H, Jennings G, Bobik A, Korner P. Norepinephrine kinetics in patients with idiopathic autonomic insufficiency. Circ Res 1980; 46: 147-148
8. Gasnier B, Roisin MP, Scherman D. Uptake of meta-iodobenzylguanidine by bovine chromaffin granule membranes. Mol Pharmacol 29 (3): 275-280, 1986
9. Glowniak JV, Kilty JE, Amara SG. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine, and serotonin transporters. J Nucl Med 1993; 34: 114-116
10. Grubb BP, Klingenleben T. Syndromes of autonomic insufficiency associated with orthostatic intolerance: Classification, diagnostic and therapeutic approach. Z Kardiol 1999; 88: 541-549
11. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: Autopsy findings and review of the literature. Acta Neuropathol 1997; 94: 192-196
12. Hale WA, Chamblis ML. Should primary care patients be screened for orthostatic hypotension? J Fam Pract 48 (7): 547-552, 1999
13. Jaques S, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: Evidence of uptake-one. Cancer Res 1987; 47: 3920-3928
14. Jaques S, Tobes MC. Comparison of the secretory mechanisms of metaiodobenzylguanidine (MIBG) and norepinephrine (NE) from the cultured bovine adrenomedullary cells. J Nucl Med 1985; 26: 17
15. Kreiner G, Wolzt M, Fasching P. Myocardial m[123I]iodobenzylguanidine scintigraphy for the assessment of adrenergic cardiac innervation in patients with IDDM: Comparison with cardiovascular reflex tests and relationship to left ventricular function. Diabetes 44 (5): 543-549, 1995
16. Langer A, Freeman MR, Josse RG. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 25 (3): 610-618, 1995
17. Mathias CJ, Mallipeddi R, Bleasdale-Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and in multiple system atrophy. J Neurol 1999; 246: 893-898
18. Mathias CJ. Orthostatic hypotension: Causes, mechanism, and influencing factors. Neurology 1995; 45: S6-S11
19. Matthews MR. Assessing the peripheral ganglia in autonomic failure. In: Bannister R (ed). Autonomic Failure, Second Edition, Oxford Medical Publications, Oxford 1988: 521-543
20. Meredith IT, Eisenhofer G, Lambert GW, Jennings GL, Thompson J, Esler MD. Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure. Hypertension 1992; 19: 628-633
21. Oppenheimer D. Neuropathology of autonomic failure. In: Bannister R (ed). Autonomic Failure, Second Edition, Oxford Medical Publications, Oxford 1988; 451-463
22. Polinsky RJ, Nee LE. Autonomic failure: Nosology, clinical evolution, and prognosis. Ann Neurol 1989; 26: 121
23. Polinsky RJ, Kopin IJ, Ebert MH, Weise V. Pharmacological distinction of different orthostatic hypotension syndromes. Neurology 1981; 31: 1-7
24. Robertson D, Robertson RM. Causes of chronic orthostatic hypotension. Arch Int Med 1994; 154: 1620-1624
25. Schnell O, Kirsch CM, Stemplinger J. Scintigraphic evidence for cardiac sympathetic dysinnervation in long-term IDDM patients with and without ECG-based autonomic neuropathy. Diabetologica 38 (11): 1345-1352, 1995
26. Silke B, Spiers JP, Boyd S, Graham E, McParland G, Scott ME. Evaluation of non-invasive blood pressure measurement by the Finapres method at rest and during dynamic exercise in subjects with cardiovascular insufficiency. Clin Autonomic Res 1994; 4: 49-56
27. Sisson JC, Wieland DM, Sherman P. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 28 (10): 1620-1624, 1987
28. Sisson JC, Shapiro B, Meyers L. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28 (10): 1625-1636, 1987
29. Sisson JC, Lynch JJ, Johnson J. Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am Heart J 1988; 116: 67-76
30. Van Ingelghem E, Van Zandijcke M, Lammens M. Pure autonomic failure: A new case with clinical, biochemical, and necropsy data. J Neurol Neurosurg Psychiatry 1994; 57: 745-747
31. Wieland DM, Mangner TJ, Inbasekaran MN. Adrenal medulla imaging agents: A structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem 1984; 27: 149-155
32. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977; 296: 293-297